Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01871311
Title A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Georgetown University
Indications
Therapies
Age Groups: adult
Covered Countries USA


No variant requirements are available.